Pharmacoepidemiologic and<i>in vitro</i>evaluation of potential drug–drug interactions of sulfonylureas with fibrates and statins

Abstract

Use of fenofibrate or gemfibrozil together with glyburide was associated with elevated overall risks of serious hypoglycaemia. CYP inhibition seems unlikely to explain this observation. We speculate that a pharmacodynamic effect of fibrates (e.g. activate peroxisome proliferator-activator receptor alpha) may contribute to these apparent interactions.